Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 7/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | PIM1 | P11309 | 2/20 | 0.33 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15873729 | 0.74 | ALDH1A1 (0.53) | ALDH1A1GAACDC7PARP1P2RX7 | |
| SCHEMBL3210392 | 0.74 | CDC7 (0.30) | CDC7 | |
| SCHEMBL947045 | 0.69 | — | — | |
| SCHEMBL22186498 | 0.67 | ALDH1A1 (0.53) | ALDH1A1GAACDC7PARP1P2RX7 | |
| SCHEMBL1412000 | 0.67 | ALDH1A1 (0.62) | ALDH1A1GAACDC7PARP1P2RX7 | |
| SCHEMBL4207853 | 0.67 | CDC7 (0.50) | ALDH1A1GAACDC7PARP1P2RX7 | |
| SCHEMBL1737418 | 0.67 | IDO1 (0.34) | IDO1 | |
| SCHEMBL24730822 | 0.66 | MAPKAPK2 (0.34) | CDC7IDO1MAPKAPK2RPS6KA3 | |
| SCHEMBL24730818 | 0.66 | MAPKAPK2 (0.34) | CDC7IDO1MAPKAPK2RPS6KA3 | |
| SCHEMBL16094212 | 0.65 | ALDH1A1 (0.43) | ALDH1A1GAAPARP1P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528918-B1 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-09-10 | — | — | EP | claimed |
| CN-119894897-A | Heteroaromatic compounds for the treatment of neurological disorders | 苏文生命科学有限公司 | 2025-04-25 | — | — | CN | disclosed |
| US-20240246984-A1 | HETEROCYCLIC JAK INHIBITOR | BEIJING INNOCARE PHARMA TECH CO., LTD. (CN) | 2024-07-25 | — | — | US | disclosed |
| WO-2024042480-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | SUVEN LIFE SCIENCES LIMITED (IN) | 2024-02-29 | — | — | WO | disclosed |
| EP-2528918-B1 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2014-09-10 | — | — | EP | disclosed |
| US-8772279-B2 | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-8772279-B2 | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-8772279-B2 | 6,7-dihydroimidazo[1,5-a]pyrazin-8(5H)-one derivatives as protein kinase modulators | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | disclosed |
| US-20130029974-A1 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-31 | — | — | US | disclosed |
| US-20130029974-A1 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-01-31 | — | — | US | disclosed |
| EP-2528918-A1 | 6,7- DIHYDROIMIDAZO [1,5-A]PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | disclosed |
| EP-2528918-A1 | 6,7- DIHYDROIMIDAZO [1,5-A]PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011092120-A1 | 6,7- DIHYDROIMIDAZO [1,5-A] PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011092120-A1 | 6,7- DIHYDROIMIDAZO [1,5-A] PYRAZIN-8 (5H) - ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029974-A1 | 6,7-DIHYDROIMIDAZO[1,5-A]PYRAZIN-8(5H)-ONE DERIVATIVES AS PROTEIN KINASE MODULATORS | MAP3K6, MAP3K1, MAP3K5 | ALDH1A1 3554/4885GAA 2443/4885CDC7 134/4885 |
| US-20240246984-A1 | HETEROCYCLIC JAK INHIBITOR | JAK2, JAK1, JAK3 | ALDH1A1 2091/4885GAA 2623/4885CDC7 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.